TB treatment study for people who just finished therapy
Part of Infections clinical trials.
This study looks for people who have recently completed standard treatment for drug-sensitive TB. Researchers want to check if certain tests can predict long-term health outcomes after treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 12 years or older
- You finished a 6-month course of the standard TB medicines (isoniazid, rifampin, pyrazinamide, and ethambutol)
- You finished treatment no more than 14 days ago
- You have not taken any antibiotics for TB or similar infections in the last 14 days (for any reason)
- You are willing to sign a consent form and come back for follow-up visits
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests personalized TB treatment schedules based on your individual risk factors. Researchers want to see if matching treatment intensity to your specific situation helps cure TB while minimizing side effects.
This trial tests a shorter treatment regimen for people with tuberculosis (TB) who don't have symptoms. If you have TB bacteria in your lungs but no cough, fever, night sweats, or weight loss, this study may offer a more convenient treatment option.
This study tests new, faster ways to diagnose tuberculosis (TB) using samples like sputum (mucus from your lungs), tongue swabs, and urine. It aims to see if these new tests can find TB more accurately than current methods, which could help you get the right treatment sooner.
This trial tests a new “triple-dose” set of medicines to treat people whose tuberculosis (TB) has come back in the lungs. If you qualify, the goal is to improve cure rates and reduce the chance of TB returning again.
This study looks at immune system blood tests in adults being treated for active tuberculosis and/or latent tuberculosis infection. The goal is to see if these “immune biomarkers” can help guide or improve tuberculosis management.
This study aims to better understand how the immune system responds to tuberculosis (TB) and improve tools for diagnosing and managing the disease. It may help people with active TB, their close contacts, people with certain other lung diseases, or healthy individuals.
Hear when a new Tuberculosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.